🔗 Share this article

The initial novel therapies for gonorrhoea in a generation are being hailed as a "significant breakthrough" in the fight against superbug strains of the pathogen, according to health experts.

A Global Challenge

Cases of gonorrhoea are on the rise globally, with estimates suggesting in excess of 82 million instances per year. Especially elevated rates are seen in the African continent and nations within the World Health Organization's designated area, which encompasses China and Mongolia to New Zealand. In England, cases have hit a historical peak, while rates across Europe in 2023 were triple the level compared to those in 2014.

“The clearance of new treatments for gonorrhoea is an critical and opportune development in the face of growing infection rates, escalating drug resistance and the extremely scarce therapeutic options currently available.”

Public health authorities are deeply concerned about the rise in drug-resistant strains. The WHO has classified it as a "high-priority threat". Ongoing monitoring found that resistance to primary antibiotics like ceftriaxone and cefixime increased dramatically between 2022 and 2024.

A Pair of Novel Therapies Receive Approval

Zoliflodacin, also known as a brand name, was approved by the US Food and Drug Administration in December for treating gonorrhoea. This infection can lead to significant complications, including the inability to conceive. Experts believe that specific application of this new drug will help slow the emergence of superbugs.

Gepotidacin, developed by the drugmaker GlaxoSmithKline, also received approval in close succession. This medication, which is additionally indicated for urinary tract infections, was demonstrated in studies to be successful in treating drug-resistant strains of the gonorrhoea bacteria.

An Innovative Approach to Creation

Zoliflodacin was the result of a innovative non-profit model for antibiotic development. The non-profit organisation Global Antibiotic Research & Development Partnership worked alongside the pharmaceutical company Innoviva to bring it to fruition.

“This approval signifies a huge turning point in the therapy of highly resistant gonorrhoea, which up to this point has been evolving faster than our drug pipeline.”

Testing Outcomes and Global Access

According to data released by a major medical journal, the new drug cured over nine in ten of cases of the STI. This places it at an equal footing with the existing first-line therapy, which combines two antibiotics. The research involved nearly 1,000 volunteers from several countries including Belgium, the Netherlands, South Africa, Thailand and the US.

Through the arrangement of its development partnership, GARDP has the rights to register and commercialise the drug in many low-income and middle-income countries.

Clinicians on the front lines have voiced positive views. The availability of a one-pill regimen such as this is described as a "revolutionary step" for gonorrhoea control. This is deemed vital to alleviate the strain of the disease for patients and to prevent the spread of highly drug-resistant gonorrhoea around the world.